

---

## Product Data Sheet

---

Product Name: RP-6685  
Cat. No.: GC67865

### Chemical Properties

Cas. No. 2832047-80-8

Formula  $C_{22}H_{14}F_7N_5O$

M.Wt 497.37

Solubility DMSO : 125 mg/mL (251.32 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

RP-6685 is a potent, selective and orally active **DNA polymerase theta (Polθ)** inhibitor with an **IC<sub>50</sub>** value of 5.8 nM (PicoGreen assay). RP-6685 shows antitumor efficacy in mouse tumor xenograft model<sup>[1]</sup>.

RP-6685 is extremely potent with an IC<sub>50</sub> of 550 pM against the pol activity of full-length Polθ and inactive on the ATPase activity<sup>[1]</sup>.

RP-6685 inhibits Polθ in HEK293 LIG4<sup>-/-</sup> cells with an IC<sub>50</sub> of 0.94 μM<sup>[1]</sup>.

RP-6685 (80 mg/kg; p.o.; BID for 21 days) exhibits potent antitumor efficacy in BRCA2-deficient HCT116 mice<sup>[1]</sup>.

Animal Model: Female CD1 nude mice (HCT116 BRCA2<sup>+/+</sup> and BRCA2<sup>-/-</sup> xenograft tumor models)<sup>[1]</sup>

Dosage: 80 mg/kg

Administration: p.o.; BID for 21 days

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Result: Showed tumor regression during the first 8 days of treatment in BRCA2<sup>-/-</sup> HCT116 model, while did not inhibit tumor growth in BRCA2<sup>+/+</sup> HCT116 tumors mice.

Animal Model: CD1 mice (20-30 g)<sup>[1]</sup>

Dosage: 2.5 mg/kg

Administration: i.v. or p.o.; single dosage

Result:	CL (mL/min/kg)	V <sub>dss</sub> (L/kg)	t <sub>1/2</sub> (h)	F (%)
	36.8	1.1	0.4	66

[1]. Bubenik M, et al. Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Pol $\theta$ . J Med Chem. 2022 Sep 20.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA